WebJun 12, 2024 · Abstract In 2014, the International Myeloma Working Group reclassified patients with smoldering multiple myeloma (SMM) and bone marrow-plasma cell … WebMar 29, 2024 · Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2024 Jul;34(7):1840-1852. …
Smoldering multiple myeloma: prevalence and current evidence …
WebHigh-risk smoldering myeloma: Perspective on watchful monitoring. In a 2008 paper, Dispenzieri and colleagues at the Mayo Clinic proposed a risk stratification system for … WebOct 25, 2024 · PURPOSE Observation is the current standard of care for smoldering multiple myeloma. We hypothesized that early intervention with lenalidomide could delay progression to symptomatic multiple myeloma. METHODS We conducted a randomized trial that assessed the efficacy of single-agent lenalidomide compared with observation in patients … grandpa was a carpenter words
National Center for Biotechnology Information
WebDec 9, 2024 · Smoldering multiple myeloma (SMM) is an asymptomatic precursor condition to multiple myeloma (MM). The prevalence of SMM is 0.5% in persons over 40 years old; it … WebFeb 8, 2024 · Inclusion Criteria:-Risk factors for progression to multiple myeloma in patients with smoldering multiple myeloma (SMM) have been identified and include: percentage of bone marrow involvement by plasma cells, monoclonal spike in blood, serum free light chains in blood, presence or absence of immunoparesis in blood, percentage of normal … WebDec 20, 2024 · ASH 2024: Daratumumab a Potential Treatment Option High Risk MGUS & Low Risk Smoldering Myeloma. Posted: Dec 20, 2024. ... High-risk MGUS is defined as <10% bone marrow plasma cells and <3g/dL M protein and at least 2 of the following 3 high-risk criteria: Abnormal serum free light chain ratio of <0.26 or > 1.6; M protein > or = 1.5g/dL; chinese meals on wheels vancouver